|
82 Companies |
|
138 Products |
|
138 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
631 News |
|
| 12345678910111213...1314» |
- | Yervoy (ipilimumab) / BMS
Phase classification, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 24, 2024
P1, N=3, Terminated, Sponsor: Stanford University
Phase classification: P1/2 --> P1
- | NN1213 / Novo Nordisk
Trial completion date: Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 20, 2019
P1, N=20, Suspended, Sponsor: National University Health System, Singapore
Phase classification: P1/2 --> P1 Trial completion date: Feb 2018 --> Feb 2020
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment change, Trial termination: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Feb 26, 2019
P2, N=20, Terminated, Sponsor: University of Nebraska
Trial completion date: Feb 2018 --> Feb 2020 N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Trial completion, Enrollment change: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Jan 28, 2019
P1, N=26, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections. Active, not recruiting-> Completed | N=42 --> 26
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, MRI: Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin (clinicaltrials.gov) - Dec 10, 2018
P=N/A, N=13, Completed, Sponsor: University of Nebraska
Active, not recruiting-> Completed | N=42 --> 26 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal: Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (clinicaltrials.gov) - Nov 26, 2018
P2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed N=30 --> 0 | Recruiting --> Withdrawn
- | Trial termination: Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=241, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
N=30 --> 0 | Recruiting --> Withdrawn Completed --> Terminated
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment closed, Enrollment change, Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Sep 19, 2018
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018
- | cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018
P2, N=142, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018 Active, not recruiting --> Completed | N=92 --> 142
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 17, 2018
P2, N=35, Completed, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed | N=92 --> 142 Active, not recruiting --> Completed
- | Trial completion date, Trial termination: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=1000, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 29, 2018
P2, N=42, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed
- | Trial completion, Biopsy: Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=83, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Recruiting --> Completed
- || Trial completion, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Jun 4, 2018
P1, N=44, Completed, Sponsor: Amir Mortazavi
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Trial completion, Enrollment change: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - May 3, 2018
P1, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active,not recruiting --> Completed | N=42 --> 26
- | Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018
P1, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Active,not recruiting --> Completed | N=42 --> 26 Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 34
- | Trial completion: Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=304, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed | N=60 --> 34 Active, not recruiting --> Completed
- | Trial completion: Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=36, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells (clinicaltrials.gov) - Jan 23, 2018
P2, N=20, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion, Combination therapy: Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P2, N=0, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P2, N=60, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Post-transplantation: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Jan 2, 2018
P2, N=63, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 63
- | New P1 trial: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Dec 19, 2017
P1, N=7, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
- | Phase classification: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Dec 19, 2017
P1, N=7, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed | N=100 --> 63 Phase classification: P=N/A --> P1
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 28, 2017
P2, N=213, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Phase classification: P=N/A --> P1 Terminated --> Completed
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment closed, Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Nov 21, 2017
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2018
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Phase classification: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Nov 17, 2017
P1, N=4, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2018 Phase classification: P=N/A --> P1
- | Gliadel Wafer (carmustine implant) / Eisai, Azurity Pharma, Rituxan (rituximab) / Roche
Trial completion: Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 3, 2017
P2, N=68, Completed, Sponsor: University of Nebraska
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Oct 2, 2017
P2, N=50, Active, not recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2017
- | Enbrel (etanercept) / Pfizer, Amgen
Clinical: Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov) - Sep 29, 2017
P2, N=39, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2014 --> Dec 2017 Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 28, 2017
P2, N=2, Terminated, Sponsor: Burzynski Research Institute
Active, not recruiting --> Completed N=40 --> 2 | Initiation date: Aug 1998 --> Apr 1996 | Active, not recruiting --> Terminated; slow accrual
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Sep 27, 2017
P1/2, N=147, Completed, Sponsor: OHSU Knight Cancer Institute
N=40 --> 2 | Initiation date: Aug 1998 --> Apr 1996 | Active, not recruiting --> Terminated; slow accrual N=204 --> 147
- | lenalidomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Sep 25, 2017
P1, N=17, Completed, Sponsor: National Cancer Institute (NCI)
N=204 --> 147 Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012
- | Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date: COMBOSTAT: Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (clinicaltrials.gov) - Sep 19, 2017
P2, N=0, Withdrawn, Sponsor: The Methodist Hospital System
Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012 Trial primary completion date: Apr 2014 --> May 2012
- | melphalan / Generic mfg.
Phase classification: Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=66, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Apr 2014 --> May 2012 Phase classification: P2 --> P=N/A
- | cyclophosphamide / Generic mfg.
Phase classification, Trial initiation date, Trial suspension: Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 25, 2017
P1, N=20, Suspended, Sponsor: National University Health System, Singapore
Phase classification: P2 --> P=N/A Phase classification: P2 --> P1 | Initiation date: Jan 2014 --> Sep 2013 | Recruiting --> Suspended
- | Bexxar (iodine I 131 tositumomab) / GSK
Trial primary completion date: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 18, 2017
P2, N=111, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P2 --> P1 | Initiation date: Jan 2014 --> Sep 2013 | Recruiting --> Suspended Trial primary completion date: Jul 2014 --> Oct 2011
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 19, 2017
P1, N=29, Completed, Sponsor: California Cancer Consortium
Trial primary completion date: Jul 2014 --> Oct 2011 Active, not recruiting --> Completed | N=40 --> 29
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=4, Completed, Sponsor: Baylor College of Medicine
Active, not recruiting --> Completed | N=40 --> 29 Active, not recruiting --> Completed | N=12 --> 4 | Trial primary completion date: Jan 2017 --> Aug 2016
- ||| denintuzumab mafodotin (SGN-CD19A) / Pfizer
Trial completion, Trial primary completion date: A Safety Study of SGN-CD19A for Leukemia and Lymphoma (clinicaltrials.gov) - Jul 2, 2017
P1, N=92, Completed, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Completed | N=12 --> 4 | Trial primary completion date: Jan 2017 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> May 2017
- ||| denintuzumab mafodotin (SGN-CD19A) / Pfizer
Trial completion: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Jul 2, 2017
P1, N=64, Completed, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> May 2017 Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=1, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=20 --> 1
- | deferasirox tablet for oral suspension / Generic mfg.
Phase classification: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 20, 2017
P2, N=16, Completed, Sponsor: Wake Forest University Health Sciences
N=20 --> 1 Phase classification: P=N/A --> P2
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - May 30, 2017
P2, N=71, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011
- | Trial completion, Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=9, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=186, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Not yet recruiting --> Completed | Trial primary completion date: Mar 2013 --> Feb 2012
- | Trial completion, Trial primary completion date, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=54, Completed, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Completed | Trial primary completion date: Mar 2013 --> Feb 2012 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Oct 2009
- | Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 18, 2017
P1, N=38, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Oct 2009 Trial primary completion date: Apr 2017 --> Dec 2017